A mixed deep eutectic solvents-based air-assisted liquid-liquid microextraction of surfactants from exhaled breath condensate samples prior to HPLC-MS/MS analysis.

A ternary solvent system-based air-assisted liquid-liquid microextraction procedure was developed for the extraction of three surfactants from exhaled breath condensate samples prior to their determination by high performance liquid chromatography-tandem mass spectrometry. In this approach, different deep eutectic solvents were synthesized based on phosphocholine chloride and fatty acids and their mixtures were used as the extraction solvents to effective extraction of the analytes. To obtain the optimum composition of the extraction solvents, a simplex centroid design approach was used. Then the effective parameters were studied by response surface methodology using central composite design. The obtained data after optimization showed that 6 times was the best extraction time for the developed procedure. When the sample solution pH was adjusted at 3.7, the method reached to higher extraction efficiency which can be related to the fact that the analytes were in the protonated forms. Increasing the sample solution temperature up to 50 °C enhanced the migration rate of the analytes into the extraction solvent and the method efficacy was increased. Also addition of sodium chloride at 2.8% (w/v) had a positive effect on the method efficiency which can be related to decreasing the analytes solubility in the sample solution. Under optimal conditions, the method showed satisfactory coefficient of determination (≥0.9979), low limit of detection (0.12-0.23 ng mL-1) and quantification (0.39-0.76 ng mL-1), acceptable repeatability in deionized water (relative standard deviation ≤ 8.2%) and in exhaled breath condensate (relative standard deviation ≤ 7.2%), and acceptable extraction recovery (75-86%) and enrichment factor (71-86). Considering these results, the developed method provided a quick and efficient way to determine surfactants in the exhaled breath condensate collected from expiratory circuit of the mechanical ventilator. It can be used in drug monitoring and clinical studies.

The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants.

Hosseini M, Azampour H, Raeisi S, Behtari M, Valizadeh H, Saboohi R. The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants. Turk J Pediatr 2019; 61: 392-398. Necrotizing Enterocolitis (NEC) is a common devastating gastrointestinal disease, which usually develops in premature infants. Erythropoietin (EPO) as a hematopoietic hormone produced by the kidney can also be naturally found in amniotic fluid and breast milk. There is some evidence that supports the contribution of EPO in the prevention of inflammation and intestinal tissue repair. This study was aimed to determine if oral administration of artificial amniotic fluid with or without EPO would protect preterm infants against NEC and improve the certain neonatal outcomes. In this study, 150 preterm infants with gestational age 28 weeks or less and birth weight 1250 grams or less were enrolled. The infants were divided randomly into 3 groups: 1) Control group (n=50) with routine feeding protocol without any administration; 2) Amniotic fluid group (n=50) with 5mL/kg synthetic amniotic fluid; 3) EPO group (n=50) with RhuEPO dissolved in the synthetic amniotic fluid. The administrations of the study solution were started 3 days after the birth and were continued for 3 weeks (21 days). The infants in the study groups were followed up until discharge and the frequency of NEC, mortality, and other complications of the disease among the groups were compared. The mortality rate in preterm infants of the amniotic fluid and EPO groups were significantly lower than in the control group (p=0.027). We couldn`t find any significant differences in the frequency of NEC and other complications among the three study groups. The administration of synthetic amniotic fluid (with or without EPO) in preterm infants may decrease the mortality rate. Use of EPO in synthetic amniotic fluid did not affect the frequency of NEC.